To evaluate the efficacy of Canakinumab in patients with Cryopyrin Associated Periodic Syndromes (CAPS)

Trial Profile

To evaluate the efficacy of Canakinumab in patients with Cryopyrin Associated Periodic Syndromes (CAPS)

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2017

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Cryopyrin-associated periodic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Mar 2017 New trial record
    • 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top